What does Alumis Inc. do?
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous…
What is Alumis Inc.'s P/E and P/B ratio?
Alumis Inc. has a P/E ratio of -1.8 and a P/B ratio of 1.95.
What is Alumis Inc.'s debt-to-equity ratio?
Alumis Inc. has a debt-to-equity ratio of 0.08.
How much does Alumis Inc. owe compared with what it owns?
Alumis Inc. owes $0.19 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Alumis Inc.'s Positivity rank?
Alumis Inc. is ranked #2,118 of 6,774 companies globally and #594 of 4,000 in United States on PositoAI, with a Positivity Score of 21,875.
Does Alumis Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Alumis Inc..
Where can I read the latest news about Alumis Inc.?
Recent headlines about Alumis Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Alumis Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Alumis Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.